

## **MedAnnex announces Dr Tina Flatau as Managing Director.**

**Edinburgh, Scotland, 2nd January 2016.**

MedAnnex Limited, a dynamic Edinburgh-based biotechnology company developing new treatments for autoimmune diseases, today announced the appointment of Dr Tina Flatau as Managing Director.

Dr Flatau has a PhD in Pharmaceutical Sciences from King's College London and began her career in product development with SmithKlineBeecham (later GSK). She was in the first Pharmaceuticals Practice team at Coopers & Lybrand/ PwC, has a special interest in growth-phase and biotech developments, and worked with rare disease company Prosensa through their successful IPO onto NASDAQ.

Dr Flatau commented *'Autoimmune diseases are wide-ranging and devastating for patients and their families. I am proud to be working with MedAnnex on their breakthrough approaches to treating autoimmune diseases. We have a great technical and supplier team, all focused on bringing our lead, Annexuzlimab® to the clinic without delay.'*

MedAnnex Chairman Professor Chris Wood said *'We have been working with Tina as an advisor for some time, and I am delighted that she will join MedAnnex as Managing Director, effective immediately.'*

### About MedAnnex

MedAnnex Ltd, based in Scotland, is a dynamic biotechnology company developing new treatments for people with autoimmune diseases. The company's lead product - Annexuzlimab® - is a humanised monoclonal antibody which, in extensive non-clinical testing, has shown significant activity in rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus.